Project Number 2R01AG020241-11A1 Agency/Funding Organization NIA Funding Year 2012 View Full Project Details for MULTIPLE APPROACHES TO ABETA VACCINATION IN ANIMAL MODELS Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 9. Immunity and Inflammation d. Immunotherapy - Mechanisms of Action Researcher and Organization Principal Investigator CRIBBS, DAVID HASTINGS Principal Investigator First Name DAVID Principal Investigator Last Name CRIBBS Awardee Organization UNIVERSITY OF CALIFORNIA IRVINE Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PA-11-260: RESEARCH PROJECT GRANT (PARENT R01) FY Overall Cost $335,943 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official REFOLO, LORENZO Related Resources Repository [AlzPED] MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice [AlzPED] Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease. [AlzPED] Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial [AlzPED] Low Concentrations of Anti-Abeta Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology [AlzPED] Reductions in Aβ-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation [AlzPED] Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. [AlzPED] Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles.
